期刊文献+

高效液相法测定盐酸乐卡地平片含量 被引量:1

Determination of the Content of Lercanidipine Hydrochloride by HPLC
下载PDF
导出
摘要 使用高效液相色谱法测定乐卡地平片含量,流动相为乙腈-0.01mol/L乙酸铵溶液-三乙胺(650∶350∶1)(pH6.0)。结果显示盐酸乐卡地平在浓度为2.05~404.0μg/mL范围内具有良好的线性关系,盐酸乐卡地平片剂的平均标示量含量为100.3%,符合要求。研究表明HPLC色谱法对乐卡地平片剂进行含量测定,具有良好的线性、稳定性及精密度,回收率高,能够用于本品的含量测定。 Determine the content of Lercanidipine Hydrochloride with high-performance liquid chromatography (HPLC). Use HPLC, mobile phase : acetonitrile-0.01 mol/L ammonium acetate solution - Triethylamine ( 650:35 : 1 ) (pH 6. 0 ). Lercanidipine Hydrochloric has good linear relationship in the scope of the concentration of 2. 05 404.0 μg/mL. The average contents of Lercanidipine Hydrochloric was 100.3% , which was in accordance with pharmacopoeial requirements. HPLC was used to determine the content of Lercanidipine Hydrochloric tablet, which has good linearity, stability, and precision, high efficiency. It can be used for the determination of Lercanidipine Hydrochloric.
出处 《激光生物学报》 CAS CSCD 2011年第5期695-698,共4页 Acta Laser Biology Sinica
基金 湖南省教育厅重点项目(10A071)
关键词 高效液相法(HPLC) 盐酸乐卡地平片 含量测定 HPLC Lercanidipine Hydrochloric content determination
  • 相关文献

参考文献10

  • 1BANG L M, CHAPMAN T M, GOA K L. Lercanipine:A Review of Its Efficacy in the Management of Hypertention [ J 1. Drugs, 2003, 63 ( 22 ) :2449-2472.
  • 2孙忠实,朱珠.乐卡地平[J].中国新药杂志,2001,10(7):545-546. 被引量:8
  • 3MILAR-CRAIG M, SHAFFU B, GREENOUGH A, et al. Ler- canipine vs Lacidipine in Isolated Systolic Hypertension [ J]. J Hum Hypertens, 2003, 17 ( 11 ) :799-806.
  • 4杨丽萍,张津枫,张广明,陈咏梅,郭立民.反相高效液相色谱法测定乐卡地平片的含量[J].天津药学,2006,18(5):16-18. 被引量:2
  • 5BARANDA A B, ALONSO R M, WEINMANN W, et al. Insta- bility of Calcium Channel Antagonists during Sample Prepa-ration for LC-MS-MS Analysis of Serum Samples[J]. Forensic Science International, 2006, 156:23-34.
  • 6黄小玉,尚京川,曲斐,杨国章,廖红.高效液相-质谱法测定人血浆中乐卡地平的浓度[J].中国医院药学杂志,2008,28(22):1939-1942. 被引量:2
  • 7SABBATINI M, TOMASSONI D, MAD T, et al. Neuroprotec- tive Effect of Treatment with Calcium Antagonists on Hyperten- sive Retina [ J ]. Clin Exp Hypertens, 2002, 24 ( 7-8 ) : 727 -740.
  • 8INCANDELA L, BELCARO G, CESARONE M R, et al. Oxy- gen-free Radical Decrease in Hypertensive Patients Treatment with Lercanipine[ J]. Int Angiol, 2001 , 20 (2) : 136-140.
  • 9程斌,刘启,余心海.高效液相色谱法测定特非那丁片溶出度[J].中国医院药学杂志,2000,20(8):471-473. 被引量:1
  • 10KOSTIS J B. Treatment of Hypertension in Older Patients: An Updated Look at the Role of Calcium Antagonists [ J]. Am J Geriatr Cardiol, 2003, 12 ( 5 ) :319-327.

二级参考文献10

  • 1周正东.特非那定的HLPC测定[J].中国医药工业杂志,1994,25(5):221-223. 被引量:1
  • 2于香安,蔡怀友.用电子计算器求算片剂溶出度溶出参数的运算程序[J].中国药房,1995,6(4):21-22. 被引量:102
  • 3Ana B, Baranda, Rosa M, Alonso, Wolf gang Weinmann, et al. Instability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples[J]. Forensic Science International, 2006,156 : 23-34.
  • 4Jabor VA,Coelho EB,Ifa DR,etal. Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography-tandem mass spectrometry[J]. Chromatogr-B, Analyt Technol Biomed Life Sci, 2003,796 (2): 429-37.
  • 5[1]McClellan KJ,Jar B.Lercanidipine,a review of its use in hypertension[J].Drugs,2000,60(5)∶1123-1240.
  • 6[2]Sabbatini M,Vitaioli L,Baldoni E,et al.Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats[J].J Pharmacol Exp Ther,2000,294(3)∶948-954.
  • 7K. Parfitt(Ed. ). The Complete Drug Reference, Martindale.32^nd ed. London: Pharmaceutical Press, 1999.897
  • 8I I Salem, J Idrees, J I Al Tamimi, et al. Selective and rapid liquid chromatography - mass spectrometry method for the determination of lercanidipine in human plasma. Journal of Chromatography B, 2004, (803):201
  • 9陈吉生,黎行山.卡托普利片溶出速率考察[J].中国医院药学杂志,1998,18(4):158-159. 被引量:2
  • 10孙忠实,朱珠.乐卡地平[J].中国新药杂志,2001,10(7):545-546. 被引量:8

共引文献8

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部